8-K: Vaxart Announces Full Year 2024 Financial Results and Business Update, Highlighting Norovirus Vaccine Progress

Vaxart reports its full year 2024 financial results, provides a business update, and highlights the initiation of a Phase 1 clinical trial for its second-generation oral norovirus vaccine.

Summary

• Vaxart announced its full year 2024 financial results and provided a business update on March 20, 2025.
• The company initiated a Phase 1 clinical trial for its second-generation oral norovirus vaccine constructs, with topline data expected as early as mid-2025.
• Vaxart is continuing per protocol follow-up for the COVID-19 Phase 2b 400-person sentinel cohort.
• As of December 31, 2024, Vaxart had $51.7 million in cash, cash equivalents, and investments, which is expected to provide runway into the fourth quarter of 2025.
• The company reported revenue of $28.7 million for 2024, compared to $7.4 million for 2023.
• The net loss for 2024 was $66.9 million, compared to $82.5 million for 2023.
• Research and development expenses were $74.2 million for 2024, compared to $68.1 million for 2023.
• General and administrative expenses were $20.8 million for 2024, compared to $22.6 million for 2023.
• Vaxart implemented a restructuring plan that led to an approximately 10% reduction of its workforce after receiving a stop work order related to the COVID Phase 2b trial.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to increased revenue and progress in the norovirus vaccine program, but tempered by the net loss and the stop work order on the COVID-19 trial.

Positives

• Vaxart initiated a Phase 1 clinical trial for its second-generation oral norovirus vaccine.
• The company has sufficient cash runway into the fourth quarter of 2025.
• Revenue increased significantly in 2024 compared to 2023, primarily from government contracts.
• A Phase 1b trial of Vaxart's first-generation oral pill norovirus vaccine candidate in elderly adults demonstrated strong and durable antibody responses.
• The net loss decreased from $82.5 million in 2023 to $66.9 million in 2024.
• Vaxart continues to advance its avian influenza program.

Negatives

• Vaxart experienced a net loss of $66.9 million for the full year 2024.
• The company received a stop work order from the U.S. government regarding its COVID-19 Phase 2b trial, leading to a restructuring plan and workforce reduction.
• Research and development expenses increased in 2024 compared to 2023.

Risks

• The stop work order on the COVID-19 Phase 2b trial could be extended or result in termination of the project.
• Clinical trial data may be subject to differing interpretations by regulatory authorities.
• Vaxart's product candidates may not be approved by the FDA or other regulatory authorities.
• The company may face manufacturing issues and delays.
• Vaxart's capital resources may be inadequate.

Future Outlook

Vaxart anticipates cash runway into the fourth quarter of 2025 and plans to continue advancing its norovirus and influenza programs. The company expects topline data from its Phase 1 norovirus trial as early as mid-2025 and may begin a Phase 2b study in the second half of 2025, pending funding.

Management Comments

• Steven Lo, Chief Executive Officer of Vaxart, stated that the company is on a mission to transform global health with oral pill vaccines.
• Mr. Lo highlighted the initiation of the Phase 1 norovirus trial and the ongoing follow-up for the COVID-19 Phase 2b trial.

Industry Context

Vaxart is focused on developing oral vaccines, which could offer advantages over traditional injectable vaccines in terms of convenience, storage, and distribution. The company's efforts in norovirus, COVID-19, and influenza align with global health priorities to combat viral diseases.

Comparison to Industry Standards

• Vaxart's approach to oral vaccine development is relatively unique compared to companies primarily focused on injectable vaccines, such as Pfizer and Moderna.
• The company's focus on mucosal immunity could differentiate its vaccines from those that primarily induce systemic immunity.
• The $51.7 million cash position is modest compared to larger pharmaceutical companies, requiring Vaxart to strategically manage its resources and seek partnerships.

Management Changes

Stakeholder Impact

• Shareholders: The financial results and progress in vaccine development could impact shareholder value.
• Employees: The restructuring plan and workforce reduction affected employees.
• Customers: Progress in vaccine development could lead to new products for customers.
• Government: Government contracts are a significant source of revenue for Vaxart.

Next Steps

• Vaxart will continue the Phase 1 clinical trial for its second-generation oral norovirus vaccine.
• The company will continue per protocol follow-up for the COVID-19 Phase 2b 400-person sentinel cohort.
• Vaxart intends to publish the results of preclinical studies for its new avian influenza vaccine candidate.
• The company will further update on the BARDA award as events warrant.

Key Dates

Keywords

Vaxart, oral vaccine, norovirus, COVID-19, influenza, clinical trial, financial results, revenue, net loss, vaccine development